{"id":"deescalation-therapy","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4298181","moleculeType":"Gene"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"De-escalation therapy involves stepping down from intensive or combination treatment regimens to simpler, less toxic alternatives once a patient has responded adequately to initial therapy. This approach aims to maintain clinical benefit while reducing cumulative drug exposure, adverse effects, and treatment burden. It is commonly applied in oncology, infectious diseases, and critical care settings.","oneSentence":"De-escalation therapy is a treatment strategy that reduces the intensity, duration, or number of therapeutic agents used after initial disease control is achieved.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:32:12.193Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various malignancies after initial response to intensive chemotherapy or combination regimens"},{"name":"Severe infections after initial intensive antimicrobial therapy"}]},"trialDetails":[{"nctId":"NCT05674175","phase":"PHASE1, PHASE2","title":"Co-administration of CART22-65s and huCART19 for B-ALL","status":"RECRUITING","sponsor":"Stephan Grupp MD PhD","startDate":"2023-01-25","conditions":"B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma","enrollment":93},{"nctId":"NCT04520139","phase":"PHASE1, PHASE2","title":"Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT","status":"NOT_YET_RECRUITING","sponsor":"University of California, Irvine","startDate":"2026-03","conditions":"Ovarian Cancer, Cognitive Impairment","enrollment":102},{"nctId":"NCT07428018","phase":"PHASE2","title":"Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib","status":"NOT_YET_RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2026-04-30","conditions":"Breast Cancer, HER2 + Breast Cancer, HR Positive","enrollment":150},{"nctId":"NCT05799612","phase":"PHASE1","title":"Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-03-22","conditions":"Angiosarcoma","enrollment":""},{"nctId":"NCT02408861","phase":"PHASE1","title":"Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-10-21","conditions":"Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection","enrollment":79},{"nctId":"NCT06000748","phase":"PHASE2, PHASE3","title":"NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2024-02-01","conditions":"Acute Kidney Injury, Cirrhosis, Portal Hypertension","enrollment":6},{"nctId":"NCT05297617","phase":"PHASE2","title":"Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2022-10-12","conditions":"Breast Cancer","enrollment":696},{"nctId":"NCT05058196","phase":"NA","title":"Patient's Choice in the Reduction of Their Treatment in Women Over 65 Year With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2021-10-01","conditions":"Breast Cancer","enrollment":104},{"nctId":"NCT06226857","phase":"PHASE3","title":"Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"City Clinical Oncology Hospital No 1","startDate":"2024-01-17","conditions":"Colorectal Neoplasms, Chemotherapy Effect, Molecular Sequence Variation","enrollment":355},{"nctId":"NCT04090281","phase":"PHASE4","title":"Implementing Precision Medicine Approaches to Guide Anti-platelet Selection","status":"UNKNOWN","sponsor":"University of Southern California","startDate":"2020-03-13","conditions":"Acute Coronary Syndrome (ACS), STEMI - ST Elevation Myocardial Infarction (MI), NSTEMI - Non-ST Segment Elevation MI","enrollment":200},{"nctId":"NCT02018055","phase":"PHASE4","title":"TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction: TALOS-AMI","status":"COMPLETED","sponsor":"The Catholic University of Korea","startDate":"2014-02-14","conditions":"Acute Myocardial Infarction","enrollment":2590},{"nctId":"NCT02619669","phase":"PHASE1","title":"Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer","status":"WITHDRAWN","sponsor":"Gary Schwartz","startDate":"2017-04-20","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT04298333","phase":"PHASE1","title":"Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer","status":"COMPLETED","sponsor":"Meabco A/S","startDate":"2009-06-27","conditions":"Metastatic Breast Cancer, Stage IV Breast Cancer","enrollment":18},{"nctId":"NCT02265445","phase":"PHASE4","title":"Deescalating Carbapenems in Hospital Setting","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-06","conditions":"Urinary Infection, Digestive Infection, Biliary Infection","enrollment":6},{"nctId":"NCT00359359","phase":"PHASE1, PHASE2","title":"A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-07","conditions":"Carcinoma, Small Cell","enrollment":26},{"nctId":"NCT02074033","phase":"","title":"Errors in Prescription Antibiotics in Ventilator-associated Pneumonia","status":"UNKNOWN","sponsor":"Federal University of Uberlandia","startDate":"2014-03","conditions":"Pneumonia","enrollment":130},{"nctId":"NCT00005642","phase":"PHASE1","title":"SU5416 in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2000-05","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Switch for a narrow spectrum beta-lactam active"],"phase":"marketed","status":"active","brandName":"Deescalation therapy","genericName":"Deescalation therapy","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"De-escalation therapy is a treatment strategy that reduces the intensity, duration, or number of therapeutic agents used after initial disease control is achieved. Used for Various malignancies after initial response to intensive chemotherapy or combination regimens, Severe infections after initial intensive antimicrobial therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}